Impact of Prenatal SARS-CoV-2 Infection on Autism Spectrum Disorder Risk

A recent study published in Translational Psychiatry delves into prenatal exposure to SARS-CoV-2 and its potential risk for autism spectrum disorder (ASD) in children. Conducted as a prospective longitudinal cohort study, the research investigates the neurodevelopmental impacts of the virus during pregnancy. Participants were from the Kaiser Permanente Northern California healthcare system, with PCR tests confirming maternal infection and electronic health records providing pediatric data.

The findings indicate that female offspring exposed to the virus in utero may face a higher ASD risk compared to male offspring, with an adjusted hazard ratio of 1.44 for maternal SARS-CoV-2 infection. Interestingly, researchers did not observe an elevated risk for speech, language, or motor delays linked to the infection. The study emphasized maternal infection's timing, particularly during the first trimester, which may increase the risk of motor delays, although this risk appears to diminish in later trimesters.

Data from the study included nearly 70,000 children aged 27-48 months, with 3.97% of pregnant women contracting the virus, mainly during the third trimester. A small percentage received COVID-19 vaccinations while pregnant. Notably, children diagnosed with neurodevelopmental disorders were more likely to have non-white mothers aged 35 or older, often with government health insurance. The authors call for further research into prenatal SARS-CoV-2 infection's severity, vaccination impact, and virus variants, advocating for studies that account for familial and socioeconomic factors to better understand these neurodevelopmental outcomes.